Spots Global Cancer Trial Database for maximum tolerated dose
Every month we try and update this database with for maximum tolerated dose cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Clinical Study of Liposomal Paclitaxel in Chinese Patients | NCT00881101 | Solid Tumor | Liposomal pacli... | 18 Years - 70 Years | Nanjing Sike Pharmaceutical Co., Ltd. | |
| A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies. | NCT00676299 | Protein Kinase ... Antineoplastic ... Clinical Trial,... Maximum Tolerat... Pharmacokinetic... Advanced Malign... Solid Malignanc... | JNJ-26483327 | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| A Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, in Patients With Advanced Solid Tumors | NCT00842335 | Advanced Solid ... | JI-101 | 18 Years - | Jubilant Innovation Ltd. | |
| Safety and Efficacy of Belinostat When Used With Standard of Care Chemotherapy for Untreated Non-small Cell Lung Cancer | NCT01090830 | Non-Small-Cell ... | Belinostat, car... | 18 Years - | Holy Cross Hospital, Florida | |
| A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma | NCT01594229 | Non-Hodgkin's L... | ABT-199 Rituximab Bendamustine | 18 Years - 99 Years | AbbVie | |
| Safety and Efficacy of Belinostat When Used With Standard of Care Chemotherapy for Untreated Non-small Cell Lung Cancer | NCT01090830 | Non-Small-Cell ... | Belinostat, car... | 18 Years - | Holy Cross Hospital, Florida | |
| Combination Trial of Patupilone and Carboplatin in Adult Patients With Advanced Solid Tumors | NCT00426582 | Advanced Solid ... | Patupilone | 18 Years - | Novartis | |
| Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas | NCT01445535 | T-Cell Peripher... Gamma Delta Hep... Subcutaneous Pa... NK T-Cell Lymph... | Rituximab Etoposide Siplizumab Prednisone Vincristine Cyclophosphamid... Doxorubicin | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Losartan + Sunitinib in Treatment of Osteosarcoma | NCT03900793 | Osteosarcoma | Losartan Sunitinib | 10 Years - 40 Years | University of Colorado, Denver | |
| Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL) | NCT01839097 | Peripheral T-ce... | Belinostat CHOP | 18 Years - | Acrotech Biopharma Inc. | |
| First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410) | NCT04882917 | Advanced Solid ... | M4076 | 18 Years - | EMD Serono | |
| Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic Leukemia | NCT02316197 | Advanced Solid ... Chronic Lymphoc... | MSC2490484A (M3... | 18 Years - | Merck KGaA, Darmstadt, Germany | |
| A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors | NCT05159700 | Advanced Solid ... Advanced Solid ... | PRJ1-3024 | 18 Years - | Zhuhai Yufan Biotechnologies Co., Ltd | |
| A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors | NCT04957290 | Metastatic Cast... | NOX66 NOX66 NOX66 NOX66 NOX66 EBRT | 18 Years - | Noxopharm Limited | |
| Safety, Tolerability, and Pharmacokinetics of CAL056 Mesylate in Patients With Resistant or Refractory Solid Tumors | NCT04686383 | Resistant or Re... | CAL056 mesylate | 18 Years - | Calgent Biotechnology Co., Ltd | |
| A Study of SC-007 in Subjects With Advanced Cancer | NCT03253185 | Colorectal Canc... Gastric Cancer | SC-007 | 18 Years - | AbbVie | |
| Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer | NCT01460537 | Neoplasms | Gemcitabine BAY80-6946 Cisplatin NaCl BAY80-6964 fixe... | 18 Years - | Bayer | |
| Safety, Tolerability, and Pharmacokinetics of CAL056 Mesylate in Patients With Resistant or Refractory Solid Tumors | NCT04686383 | Resistant or Re... | CAL056 mesylate | 18 Years - | Calgent Biotechnology Co., Ltd | |
| Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors | NCT02313012 | Neoplasm Metast... | CC-90003 | 18 Years - | Celgene | |
| Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma | NCT03328104 | Lymphoblastic L... Lymphoblastic L... | Everolimus Nelarabine Cyclophosphamid... Etoposide | 2 Years - 29 Years | Emory University | |
| Temsirolimus in Combination With Metformin in Patients With Advanced Cancers | NCT01529593 | Advanced Cancer... | Temsirolimus Metformin | 14 Years - | M.D. Anderson Cancer Center | |
| Dose-escalation Study of Lupartumab Amadotin (BAY1129980) | NCT02134197 | Neoplasms | Lupartumab Amad... | 18 Years - | Bayer | |
| Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma | NCT01610570 | Ewing Sarcoma Sarcoma | Mithramycin | 1 Year - | National Institutes of Health Clinical Center (CC) | |
| ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer | NCT01675128 | Colorectal Neop... Colorectal Carc... Colorectal Tumo... | ISIS 183750 Irinotecan | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors | NCT05315167 | Advanced Solid ... Advanced Solid ... | PRJ1-3024 | 18 Years - | Zhuhai Yufan Biotechnologies Co., Ltd | |
| A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma | NCT01594229 | Non-Hodgkin's L... | ABT-199 Rituximab Bendamustine | 18 Years - 99 Years | AbbVie | |
| A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer | NCT01685489 | Prostatic Neopl... | Docetaxel, PSK® Docetaxel, Plac... | 18 Years - | Bastyr University | |
| Clinical Study of Liposomal Paclitaxel in Chinese Patients | NCT00881101 | Solid Tumor | Liposomal pacli... | 18 Years - 70 Years | Nanjing Sike Pharmaceutical Co., Ltd. | |
| A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma | NCT05100628 | Metastatic Soft... | NOX66 NOX66 NOX66 NOX66 Doxorubicin | 18 Years - | Noxopharm Limited | |
| Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer | NCT02007005 | Superficial Bla... | abnobaVISCUM Fr... | 18 Years - 80 Years | Abnoba Gmbh | |
| A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF | NCT01787552 | Primary Myelofi... Thrombocytosis Essential Throm... Polycythemia Ve... Myeloproliferat... Bone Marrow Dis... Hematologic Dis... Blood Coagulati... Blood Platelet ... Hemorrhagic Dis... | LDE225 INC424 | 18 Years - | Novartis | |
| A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX) | NCT02630368 | Solid Tumors Soft-tissue Sar... Breast Cancer | Cyclophosphamid... Cyclophosphamid... Cyclophosphamid... Avelumab and JX... | 18 Years - | Institut Bergonié | |
| A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors | NCT05315167 | Advanced Solid ... Advanced Solid ... | PRJ1-3024 | 18 Years - | Zhuhai Yufan Biotechnologies Co., Ltd | |
| Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL | NCT02361346 | Non-Hodgkin's B... Leukemia, Lymph... Small Lymphocyt... Diffuse Large B... Blood Cancer Hematological M... | MT-3724 Phase 1 MT-3724 Phase 2 | 18 Years - | Molecular Templates, Inc. | |
| Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia | NCT01794702 | Leukemia | Decitabine Idarubicin Cytarabine Clofarabine | 18 Years - 64 Years | M.D. Anderson Cancer Center | |
| Carbon Nanoparticle-Loaded Iron [CNSI-Fe(II)] in the Treatment of Advanced Solid Tumor | NCT06048367 | Advanced Solid ... Lung Cancer Pancreas Cancer Breast Cancer Thyroid Cancer Colorectal Canc... Cervical Cancer Ovarian Cancer Vulva Cancer | CNSI-Fe(II) 30 ... CNSI-Fe(II) 60 ... CNSI-Fe(II) 90 ... | 18 Years - 75 Years | Sichuan Enray Pharmaceutical Sciences Company | |
| Dose Escalation Study of Liposomal Paclitaxel With/Without Capecitabine in Patients With Advanced Gastric Carcinoma | NCT00639522 | Gastric Carcino... | Liposomal pacli... | 18 Years - 65 Years | Nanjing Sike Pharmaceutical Co., Ltd. | |
| Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) | NCT01895842 | Leukemia | Ruxolitinib | 18 Years - | M.D. Anderson Cancer Center | |
| Losartan + Sunitinib in Treatment of Osteosarcoma | NCT03900793 | Osteosarcoma | Losartan Sunitinib | 10 Years - 40 Years | University of Colorado, Denver | |
| A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma | NCT01594229 | Non-Hodgkin's L... | ABT-199 Rituximab Bendamustine | 18 Years - 99 Years | AbbVie | |
| A Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, in Patients With Advanced Solid Tumors | NCT00842335 | Advanced Solid ... | JI-101 | 18 Years - | Jubilant Innovation Ltd. | |
| AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors | NCT01362803 | Neurofibromatos... Neurofibromatos... NF1 Neurofibroma, P... | AZD6244 | 2 Years - 18 Years | National Institutes of Health Clinical Center (CC) | |
| Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM) | NCT02179515 | Lung Cancer Breast Cancer Prostate Cancer Tumors (Others) Ovarian Cancer | MVA-brachyury- ... | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer | NCT01411410 | Neoplasms | Paclitaxel Copanlisib (BAY... | 18 Years - | Bayer | |
| Dose Escalation Study of Liposomal Paclitaxel With/Without Capecitabine in Patients With Advanced Gastric Carcinoma | NCT00639522 | Gastric Carcino... | Liposomal pacli... | 18 Years - 65 Years | Nanjing Sike Pharmaceutical Co., Ltd. | |
| Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors | NCT02168725 | Neoplasms Advanced Solid ... | briciclib | 18 Years - | Traws Pharma, Inc. | |
| Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL | NCT00738829 | Leukemia, Lymph... | Lenalidomide Fludarabine Rituximab | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma | NCT01328626 | Chronic Lymphoc... Non-Hodgkin Lym... | ABT-199 | 18 Years - 99 Years | AbbVie | |
| A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors | NCT04957290 | Metastatic Cast... | NOX66 NOX66 NOX66 NOX66 NOX66 EBRT | 18 Years - | Noxopharm Limited | |
| Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel | NCT00239135 | Keratosis | PEP005 | 18 Years - | Peplin | |
| NHS-IL12 for Solid Tumors | NCT01417546 | Epithelial Neop... Epithelial Tumo... Malignant Mesen... | NHS-IL-12 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas | NCT01445535 | T-Cell Peripher... Gamma Delta Hep... Subcutaneous Pa... NK T-Cell Lymph... | Rituximab Etoposide Siplizumab Prednisone Vincristine Cyclophosphamid... Doxorubicin | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer | NCT01222780 | Sarcoma Neuroblastoma Wilms Tumor Leukemia Lymphoma Brain Tumors | Marqibo | 2 Years - 20 Years | Acrotech Biopharma Inc. | |
| Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma | NCT01610570 | Ewing Sarcoma Sarcoma | Mithramycin | 1 Year - | National Institutes of Health Clinical Center (CC) | |
| A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors | NCT01182883 | Brain Stem Neop... Glioma Pinealoma | IMC-A12 Temsirolimus | 1 Year - 21 Years | National Institutes of Health Clinical Center (CC) | |
| A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas | NCT01132911 | Lymphoma Sarcoma WilmsTumor Neuroblastoma | Vorinostat (SAH... Velcade (PS-341... | 1 Year - 21 Years | National Institutes of Health Clinical Center (CC) | |
| AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors | NCT01362803 | Neurofibromatos... Neurofibromatos... NF1 Neurofibroma, P... | AZD6244 | 2 Years - 18 Years | National Institutes of Health Clinical Center (CC) | |
| Cancer Vaccine Targeting Brachyury Protein in Tumors | NCT01519817 | Neoplasms Malignant Solid... Colon Neoplasms Adenocarcinoma | GI-6301 (Yeast ... | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL | NCT02361346 | Non-Hodgkin's B... Leukemia, Lymph... Small Lymphocyt... Diffuse Large B... Blood Cancer Hematological M... | MT-3724 Phase 1 MT-3724 Phase 2 | 18 Years - | Molecular Templates, Inc. | |
| T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery | NCT03190967 | Breast Cancer Brain Metastasi... Brain Cancer | T-DM1 TMZ | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors | NCT03496519 | Solid Tumor, Ad... | Dose Escalation... Dose Expansion ... | 18 Years - 99 Years | University of Colorado, Denver | |
| A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer | NCT03035279 | Colorectal Canc... | SC-006 ABBV-181 | 18 Years - | AbbVie | |
| Selinexor as Single Agent and With Imatinib in Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (SeliGIST) | NCT04138381 | Maximum Tolerat... GIST Metastatic Adul... Drug Toxicity Drug Use | Selinexor Imatinib | 18 Years - | Grupo Espanol de Investigacion en Sarcomas | |
| NHS-IL12 for Solid Tumors | NCT01417546 | Epithelial Neop... Epithelial Tumo... Malignant Mesen... | NHS-IL-12 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer | NCT01222780 | Sarcoma Neuroblastoma Wilms Tumor Leukemia Lymphoma Brain Tumors | Marqibo | 2 Years - 20 Years | Acrotech Biopharma Inc. | |
| A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors | NCT04903873 | Solid Tumor Renal Cell Canc... Non-Small Cell ... Renal Cell Carc... Prostate Cancer | EU101 | 18 Years - | Eutilex | |
| Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms | NCT00407498 | Neoplasm | P276-00 | 18 Years - | Piramal Enterprises Limited | |
| A Study of DBPR112 in Patients With Head and Neck Cancer and EGFR Mutated Lung Cancer | NCT03246854 | Head and Neck C... NSCLC | DBPR112 | 18 Years - 70 Years | National Health Research Institutes, Taiwan | |
| Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma | NCT03328104 | Lymphoblastic L... Lymphoblastic L... | Everolimus Nelarabine Cyclophosphamid... Etoposide | 2 Years - 29 Years | Emory University | |
| Carbon Nanoparticle-Loaded Iron [CNSI-Fe(II)] in the Treatment of Advanced Solid Tumor | NCT06048367 | Advanced Solid ... Lung Cancer Pancreas Cancer Breast Cancer Thyroid Cancer Colorectal Canc... Cervical Cancer Ovarian Cancer Vulva Cancer | CNSI-Fe(II) 30 ... CNSI-Fe(II) 60 ... CNSI-Fe(II) 90 ... | 18 Years - 75 Years | Sichuan Enray Pharmaceutical Sciences Company | |
| Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL | NCT00738829 | Leukemia, Lymph... | Lenalidomide Fludarabine Rituximab | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| Treatment of High-grade Gliomas Using Hypofractionated Radiation Therapy -a Phase I Clinical Trial | NCT03082846 | Glioma Radiotherapy, I... Maximum Tolerat... | hypofractionate... Temozolomide ch... | 18 Years - 70 Years | The Second Hospital of Hebei Medical University | |
| A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors | NCT04903873 | Solid Tumor Renal Cell Canc... Non-Small Cell ... Renal Cell Carc... Prostate Cancer | EU101 | 18 Years - | Eutilex | |
| NHS-IL12 for Solid Tumors | NCT01417546 | Epithelial Neop... Epithelial Tumo... Malignant Mesen... | NHS-IL-12 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Dose Escalation Study of Liposomal Paclitaxel With/Without Capecitabine in Patients With Advanced Gastric Carcinoma | NCT00639522 | Gastric Carcino... | Liposomal pacli... | 18 Years - 65 Years | Nanjing Sike Pharmaceutical Co., Ltd. | |
| Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors | NCT02168725 | Neoplasms Advanced Solid ... | briciclib | 18 Years - | Traws Pharma, Inc. | |
| M1231 in Participants With Solid Tumors | NCT04695847 | Metastatic Soli... Esophageal Canc... Non-Small Cell ... | M1231 M1231 | 18 Years - | EMD Serono | |
| ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer | NCT01675128 | Colorectal Neop... Colorectal Carc... Colorectal Tumo... | ISIS 183750 Irinotecan | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT02676323 | Acute Myeloid L... Myelodysplastic... | Panobinostat Fludarabine Cytarabine Intrathecal Tri... Leucovorin | - 24 Years | St. Jude Children's Research Hospital | |
| Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms | NCT00407498 | Neoplasm | P276-00 | 18 Years - | Piramal Enterprises Limited |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
